Speech by Chancellor Olaf Scholz at the groundbreaking ceremony for a diagnostics production center at Roche on November 28, 2024, in Penzberg:

Germany Olaf Scholz · Member of the Bundestag

28 November 2024 · Groundbreaking ceremony for a diagnostics production center at Roche · Roche site, Penzberg, Germany

Context
Scholz addressed the groundbreaking ceremony for Roche's new diagnostics production center in Penzberg, Germany, on November 28, 2024.
Main themes
Biotechnology and medical research, pharmaceutical industry investment, diagnostics production, AI in healthcare, regulatory reform, Germany as research location, industrial transformation, data utilization for research, personalized medicine, economic competitiveness, Roche Penzberg expansion
Duration
~10 min
37th percentile
Words
1,249
37th percentile
Sentences
78
51st percentile
Readability
56
78th percentile
Grade
9.4
15th percentile
Syntax
2.81
23rd percentile
Vocabulary
2.02
12th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 60%59%
  • Social 14%14%
  • Ceremonial 10%10%
  • Institutional 8%8%
  • Technological 4%4%
  • Environmental 3%3%
  • Geopolitical 1%1%
  • Not in focus 1%

78 sentences in 19 paragraphs

Dear Mr. Schinecker,

dear Minister President Söder,

ladies and gentlemen!

Outside the factory premises stands a large double helix, a structure that looks like a twisted ladder, eight meters high. We just passed by it. This DNA structure is the blueprint for life. Here at Roche, this is of course clear to everyone – after all, our DNA is an important component for much of what you develop here: better diagnostics, more effective medicine, a healthier life, and thus a better life.

The researcher Rosalind Franklin was the first to make the elegant structure of DNA visible, even though the Nobel Prize for this discovery was later awarded to three male colleagues. The modern biotechnology industry ultimately rests on this scientific breakthrough. Even today, biotechnology is a very important part of the research and industrial landscape in Germany – and it is growing.

Penzberg has 17,000 inhabitants. Almost 8,000 employees from Germany and more than 80 countries around the world work at Roche. Just these numbers alone show the dimension and significance of this location for the region, for Bavaria, and for all of Germany.

One more thing is very clear here at Roche in Penzberg: that we do not need to fear change. Yes, on the contrary: change is part of it if we want to have a strong industry and good jobs as a country and as an economy in 10, 20 years.

Penzberg is an old mining town. Mining is part of its DNA. This became very clear during the construction work: we are essentially standing above the old coal shafts. But something new has emerged on these shafts. Where coal was once mined, the future is now being built.

This is what the employees in production do, who manufacture antibodies here. This is what the researchers from around the world do, who are working on new molecules here. It was the men and women of Roche who developed PCR tests for the Covid-19 virus in just 38 days and then supplied the whole world with them. They saved lives – not because they did everything as usual, but because they used all their knowledge and skills. They responded quickly and correctly to a completely new situation. Germany can do that.

We can do this in Germany – large global corporations like Roche just as much as the countless medium-sized companies across the country that are highly flexible, or family businesses. They invest more than the global competition in training and research. We can do this in Germany because we have women and men like you here at Roche, who have made this company and this location great. You continuously develop it with your ideas and your skills. For that, I would like to express my heartfelt thanks to you at this point!

Germany has what it takes to be among the world leaders in medical research and biotechnology. And that is exactly where Germany belongs. However – we know this – it does not happen by itself.

When I took office as Chancellor three years ago, I regularly dealt with many pharmaceutical companies due to the pandemic. All the CEOs told me: We have great people in Germany, but if I want to build a new plant, if I need research data, if I want to develop and approve a new drug, everything takes much too long here. Germany is really cumbersome: countless regulatory authorities, super complicated data protection, requirements from Brussels, from the federal government, from the states, long deadlines. You all know what I mean. It was clear to me: this cannot continue. I will not watch as pharmaceutical research moves abroad because we have become too complicated and too sluggish here.

We sat down together, again and again, and bundled everything into a pharmaceutical strategy. We adopted it at the end of last year. With the Medical Research Act, we have gained momentum – a momentum that we still need and want. We have cleared the way through the jungle of regulatory and supervisory authorities.

A second major concern of the research-based pharmaceutical companies was more and better data for research. Unfortunately, the name of the corresponding law is a bit cumbersome: Health Data Utilization Act. But in truth, it makes the work of researchers easier. With the Health Research Data Center, we have made a significant treasure trove of data accessible for research.

Especially for what you are doing and planning here in Penzberg, data is needed. You use this data with artificial intelligence (AI). I have heard that around 100 AI experts in pharmaceuticals and diagnostics are employed here in Penzberg; that is probably true. You use AI when developing biomarkers and drugs, but also very practically for inventory management and production. This not only brings economic success. It also provides an advantage for those who urgently need new personalized and innovative therapies. Making sick people healthy faster is what it’s all about – or as they say here at Roche: “Doing now what patients need next.”

You can see the progress here in Penzberg and also at the many other groundbreaking projects in the pharmaceutical and biotechnology sector across the country. I was able to be part of some of them. Things are really moving forward in Germany. National and international companies have announced more than seven billion euros in investments in the pharmaceutical location Germany. This has not happened at this scale for years. Because you usually only hear when jobs are being cut, I want to add: The pharmaceutical and biotechnology sector has created significantly over 10,000 new jobs here in Germany since last year. It has generated 95 billion euros in gross value added in recent years, with a rising trend. The pharmaceutical industry is thus one of the most productive sectors of the economy that we have. The growth potential remains enormous.

You can see that here as well: All together – we have heard the individual amounts – you are investing more than one billion euros in this location here in Penzberg and in the future. Also, the fact that the Fraunhofer Society – as mentioned – is establishing a location next door and is already working with you is a very important signal: transfer between science and industry is taking place here. This is important – especially for a research-intensive sector like yours.

Speaking of "research," I would like to make one final remark: As the only major economy in Europe, we have been investing more than three percent of our gross domestic product in research and development for several years. This is crucial for our future as an industrial nation. We are the third largest economy in the world, also because we invest so much money in research and development. The pharmaceutical industry is the most research-intensive sector in Germany. One could also say: research is in your DNA. That’s a good thing!

Rosalind Franklin, whom I mentioned at the beginning, did not live to see what all has emerged from her sensational image of a DNA structure. She was not yet 40 years old when she died of cancer. Today, her illness could have been diagnosed earlier and thus treated better. That medical breakthroughs succeed, we owe primarily to women and men like you, women and men who work and research on therapies and diagnostics from which patients around the world benefit. I wish you all the best and much success in the future and above all: thank you very much!